Difference between revisions of "Lenograstim (Granocyte)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
Line 5: | Line 5: | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
+ | |||
+ | ==History of changes in PMDA indication== | ||
+ | *2022-06-20: New indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory [[acute myeloid leukemia]]. | ||
==Also known as== | ==Also known as== |
Revision as of 14:41, 6 June 2023
This drug is not available in the United States but is available internationally.
Diseases for which it is used
Note that colony stimulating factors are used for their adjuvant effect e.g. removing leukemia stem cells from their protective niches; they are not thought to have inherent anti-cancer activity.
History of changes in PMDA indication
- 2022-06-20: New indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory acute myeloid leukemia.
Also known as
- Brand names: Granocyte, Neutrogin